Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Multiple Molecules See UK Prices More Than Double In December

18 Jan 2022

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Scrip

Quick Listen: Scrip's Five Must-Know Things

17 Jan 2022

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

Alaric DeArment 10 Jan 2022

CancerCells_Creations_223873720_1200x675

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

Pharma intelligence for marketing agencies

Supporting market access strategy

Our unique strengths

Understand your clients’ world

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product Brand List

HBW Insight: Health, Beauty and Wellness

Generics Bulletin

Pink Sheet: global policy and regulatory coverage

Pharma Intelligence latest insights

Multiple Molecules See UK Prices More Than Double In December

Quick Listen: Scrip's Five Must-Know Things

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

Latest headlines

Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

P&G Launches Its Highest Strength Omega-3 Under Seven Seas Brand In UK

Medicines For Ireland Appoints New Chairs Following Framework Agreement

UK Regulator Calls For More Patient Involvement In Trial Design

Hangover Cures Might Work, But Evidence Weak – Study

Finance Watch: SPACs Lose Their Luster As Difficulties Mount

Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space

IGBA Appoints Frittelli As 2022 Chair

Selling Consumer Division To Unilever Could Give ‘New GSK’ A Lift

In Case You Missed It … News On Cheaper CAR-Ts, EU Approval Records, And More

The EU’s New Clinical Trial System Is Just Two Weeks Away: Are You Ready?

American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch

People On The Move: Appointments At GSK, Reckitt And Norgine

Chinese Firms At JPM Not About China, It’s Time To Go Global

EU New Drug Approvals Hit Record High

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store